Targeting NPC1 in Renal Cell Carcinoma
Cancers · 25.01.2024 · 16 (3) · 517
DOI: 10.3390/cancers16030517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 25.01.2024. Verfasst von Rushaniya Fazliyeva und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Department of Defense Idea Development.
Abstract (Originalsprache)
Rapidly proliferating cancer cells have a greater requirement for cholesterol than normal cells. Tumor cells are largely dependent on exogenous lipids given that their growth requirements are not fully met by endogenous pathways. Our current study shows that ccRCC cells have redundant mechanisms of cholesterol acquisition. We demonstrate that all major lipoproteins (i.e., LDL, HDL, and VLDL) have a comparable ability to support the growth of ccRCC cells and are equally effective in counteracting the antitumor activities of TKIs. The intracellular trafficking of exogenous lipoprotein-derived cholesterol appears to be distinct from the movement of endogenously synthesized cholesterol. De novo synthetized cholesterol is transported from the endoplasmic reticulum directly to the plasma membrane and to the acyl-CoA: cholesterol acyltransferase, whereas lipoprotein-derived cholesterol is distributed through the NPC1-dependent endosomal trafficking system. Expression of NPC1 is increased in ccRCC at mRNA and protein levels, and high expression of NPC1 is associated with poor prognosis. Our current findings show that ccRCC cells are particularly sensitive to the inhibition of endolysosomal cholesterol export and underline the therapeutic potential of targeting NPC1 in ccRCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
- Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
- Department of Urology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
ORCID-Profile: Rushaniya Fazliyeva
Förderung
- NCI NIH HHS
- National Institutes of Health
- Department of Defense Idea Development
- MPI FCCC pilot application
- NCI Core
Zitieren
APA
Fazliyeva, R., Makhov, P., Uzzo, R. G., & Kolenko, V. M. (2024). Targeting NPC1 in Renal Cell Carcinoma. Cancers, 16(3), 517. https://doi.org/10.3390/cancers16030517
Vancouver
Fazliyeva R, Makhov P, Uzzo RG, Kolenko VM. Targeting NPC1 in Renal Cell Carcinoma. Cancers. 2024;16(3):517. doi:10.3390/cancers16030517
BibTeX
@article{Fazliyeva2024,
author = {Fazliyeva, Rushaniya and Makhov, Peter and Uzzo, Robert G and Kolenko, Vladimir M},
title = {Targeting NPC1 in Renal Cell Carcinoma},
journal = {Cancers},
year = {2024},
volume = {16},
number = {3},
pages = {517},
doi = {10.3390/cancers16030517}
}
EUVIMED